Pediatric Acetazolamide Dosing Range
Acetazolamide dosing in children is indication-specific. Common pediatric dose ranges for acetazolamide are available for prevention of acute mountain sickness and for treatment of pediatric pseudotumor cerebri. [1]-[3]
Indication-Specific Dose Ranges
Acute mountain sickness prevention (high altitude)
- 1.25 mg/kg per dose PO every 12 hours with a maximum of 125 mg per dose is recommended for pediatric prevention of acute mountain sickness. [1,2]
- A prevention regimen of 2.5 mg/kg per day divided every 12 hours corresponds to the above dosing strategy. [2]
Acute mountain sickness treatment / high-altitude cerebral edema treatment
- 2.5 mg/kg per dose PO every 12 hours with a maximum of 250 mg per dose is recommended for pediatric treatment of acute mountain sickness and high-altitude cerebral edema. [2,4]
Pediatric pseudotumor cerebri (idiopathic intracranial hypertension)
- 15–25 mg/kg/day PO divided into 2–3 doses is recommended as a starting dose range for acetazolamide in pediatric pseudotumor cerebri. [3]
- The dose may be gradually increased up to 100 mg/kg/day as needed, with cited limits of maximum 2 g/day in children and maximum 4 g/day in adolescents. [3]
Medication Selection Considerations
- Acetazolamide dosing is selected based on the clinical syndrome because pediatric dosing differs for altitude illness versus pseudotumor cerebri. [1]-[3]
Treatment Initiation Thresholds
- For altitude illness prophylaxis, acetazolamide is used as a preventive agent when travel risk and ascent plans indicate need for prophylaxis. [1,2]
- For pediatric pseudotumor cerebri, acetazolamide is typically used in the context of confirmed diagnosis and specialist management. [3]
Common Pitfalls to Avoid
- Using an altitude-illness pediatric dose regimen for pseudotumor cerebri can result in underdosing or overdosing because the mg/kg/day targets differ substantially by indication. [1]-[3]
Targets and Goals of Therapy
- For pediatric altitude illness prophylaxis, the therapeutic goal is symptom prevention during ascent and the early period at altitude. [1,2]
- For pediatric pseudotumor cerebri, the therapeutic goal is reduction of intracranial pressure effects and monitoring for clinical response during dose titration. [3]
Key Evidence Supporting These Dose Ranges
- The Wilderness Medical Society 2024 guideline provides pediatric dosing for altitude illness prevention and treatment using weight-based dosing with per-dose maximums. [2,4]
- A pediatric pseudotumor cerebri evidence synthesis describes recommended starting doses and titration ceilings for acetazolamide expressed in mg/kg/day with caps. [3]